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Abstract
Radiation therapy is a useful and standard tumor treatment strategy. Despite recent
advances in delivery of ionizing radiation, survival rates for some cancer patients are still
low because of recurrence and radioresistance. This is why many novel approaches have
been explored to improve radiotherapy outcome. Some strategies are focused on enhance-
ment of accuracy in ionizing radiation delivery and on the generation of greater radiation
beams, for example with a higher dose rate. In the present study we proposed an in vitro
research of the biological effects of very high dose rate beam on SK-Mel28 and A375, two
radioresistant human melanoma cell lines. The beam was delivered by a pulsed plasma
device, a “Mather type” Plasma Focus for medical applications. We hypothesized that this
pulsed X-rays generator is significantly more effective to impair melanoma cells survival
compared to conventional X-ray tube. Very high dose rate treatments were able to reduce
clonogenic efficiency of SK-Mel28 and A375 more than the X-ray tube and to induce a
greater, less easy-to-repair DNA double-strand breaks. Very little is known about biological
consequences of such dose rate. Our characterization is preliminary but is the first step
toward future clinical considerations.
Introduction
Radiation therapy (RT) is a key component of cancer treatment; approximately 50% of all
patients with cancer receive RT at some points during the course of treatment, alone or in
combination with surgery and/or chemotherapy [1–3]. Although this local treatment modality
may improve survival and quality of patients’ life even in late stages of their disease, a large
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fraction of them subsequently develops radioresistance and recurrence [1, 4, 5]. Novel strate-
gies are urgently needed to overcome tumor radioresistance and thus improve RT outcome. In
the last decade, many studies have been aimed at enhancing biological effects of radiotherapy
according to two main approaches. One, biologic, is related to radiosensitization of tumor cells
(without sensitizing normal tissue cells), mostly through targeted and immune therapies [6–
11]. The other one, technologic, is more focused on improvement of accuracy in delivering
ionizing radiation (IR) and on generation of greater radiation beams, for example with a
higher dose rate (DR), to counteract radioresistance [3, 12–18]. DR, the quantity of radiation
absorbed per unit time, is one of the principal factors determining the biological consequences
of a given absorbed dose. As the DR is increased and the exposure time reduced, the biological
effects are generally more significant [12, 19, 20]. A number of in vitro studies have been con-
ducted and a wide range of DRs has been used, between the seventies and the nineties, to assess
the low-Linear Energy Transfer (LET) dose-rate effect. In general, it was observed that the cell
killing effect of X or γ rays decreased continuously as the dose-rate decreased due to repair of
sub-lethal damage taking place during irradiation [21]. At lower dose-rates, cell proliferation
continued during irradiation and the ultimate outcome was a complex overlapping of cellular
radiosensitivity, dose/cell cycle and tissue adaptability [19, 22, 23]. However, concerning the
very high dose-rates, the state of knowledge of mammalian cells exposition was not so evident
[20]. Recent developments in external beam radiotherapy, the emergence of intensity-modu-
lated techniques and new protocols for altered fractionation have pushed renewed interest on
the potential use of very high dose-rate in radio-response in certain treatment settings [16, 17].
A detailed insight on the DR effects in in vivo experiments with pulsed irradiation (FLASH)
has been given by Favaudon et al [24]. However, our source turned out to be radically different
with respect to pulse length and energy range (this one more comparable for instance with the
IntraBeam1) and it gave us momentum to in vitro investigate the irradiation effects of a
Plasma Focus source. The pulsed plasma device under evaluation, a “Mather type” Plasma
Focus (Plasma Focus for Medical Applications #3, PFMA-3) has been recently developed at
the University of Bologna (Montecuccolino Laboratory) for a possible application to radio-
therapy treatment of malignant cells. PFMA-3 has been geared as a pulsed X-rays generator.
The low-energy (up to 200 keV) X-rays produced by conversion on a brass target of the self-
collimated electron beam generated by the device during the pinch phase are able to deliver a
very high DR as shown in Table 1 where the main PFMA-3 features are summarized [25].
PFMA-3 is superior in terms of intensity and DR in comparison with other standard tech-
nologies like LINACs and X-rays tubes. PFMA-3 is able to deliver a dose of the order of 0.2–1
Gy/pulse, each pulse lasting 20 to 50 × 10−9 sec. On the contrary, other technologies can gener-
ally reach fractions of Gy in the order of one second or more (see Table 2).
Table 1. Technical characteristics of the PFMA-3 source.
PFMA-3 main working parameters [26, 27]
Operating Voltage [kV] 18
Primary Electron Bunch [mC] 0.1
Primary Electron Spectrum Energy Bulk [keV] 50–80
Photon Spectrum Energy Bulk [keV] 30–60
Pulse Duration [s] 20×10−9–50×10−9
Pulse Frequency [Hz] 0.1
Actual working value without cooling system.
https://doi.org/10.1371/journal.pone.0199312.t001
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In the present study, we explored PFMA-3 biological effectiveness on SK-Mel28 and A375,
two human melanoma cell lines characterized by radioresistance [31] in comparison with a
conventional X-ray tube (XRT), calibrated to mimic the PFMA-3 energy spectrum. Little is
known about molecular effects of very high DR. This report is, at our knowledge, the first
attempt to describe the advantages of such dose rates on enhancing melanoma cells radiosensi-
tivity through the study of biological effects.
Materials and methods
Radiation sources
High-DR (order of 0.2–1 Gy per shot, each shot lasting 20–50 ns) experiments were performed
with the PFMA-3 device (Montecuccolino Laboratory, University of Bologna). The Monte
Carlo simulation of the X-ray spectrum exhibited a component at 10 keV, and a component at
50 keV with a tail of up to 200 keV [32]. The dose assessment delivered in each shot has been
extensively validated using Gafchromic1 films (EBT2/3) [26]. It was referred from dose mea-
surements that photons reaching the cell layer had energies above 30 keV. Low-DR (order of
10-1Gy min-1) experiments were performed with a BALTEAU CSC320/70 X-ray tube (COME-
CER S.p.A.-ACCREDIA LAT 065), with a mean energy spectrum of 37.3 keV. Taking into
account that the X-ray device had an affective dose-rate delivery of approximately 0.2 Gy/min
and that the PFMA-3 delivered its dose of nearly 0.2–0.3 Gy/shot in few tens of ns with one
minute for cooling between shots, the “total exposure time” for the two devices could be con-
sidered comparable.
Cell culture
The human skin melanoma cell lines SK-Mel28 and A375 were obtained from the ATCC
(Catalog number: HTB-72) and from Istituto Zooproflilattico Sperimentale della Lombardia e
dell’Emilia Romagna (Catalog number: BS TCL 88) respectively. They were both cultured as
recommended. They were grown on 25–175 cm2 tissue culture flasks containing Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with 10% heat-inactivated fetal bovine
serum, 1% L-glutamine and 0.5% penicillin/streptomycin (all reagents were purchased by
Sigma-Aldrich, St Louis, MO, USA). Cells were maintained in a humified 5% CO2 air incubator
at 37˚C. Twenty-four hrs before irradiation cells were harvested at near confluence with 0.1%
trypsin (Sigma-Aldrich). Cells were plated at the same density as a monolayer on Mylar1 foils
positioned in a special holder for irradiation. They were irradiated with 2, 4, 8 Gy under PFMA-
3 and comparatively under XRT. Control and irradiated cells were subsequently detached,
counted and then seeded according to the experimental timeline schedule (up to 120hrs).
Table 2. Comparison between the PFMA-3 [26, 28] and other technologies. Given the energy range, a direct evaluation against X-ray sources can be made [27, 29].
LINACs [16, 30] sources here added as reference, have higher energies than PFMA-3 and constitute a widespread technology and a common standard for radiotherapy.
PFMA-3 X-RAY TUBE LINAC
ACCELERATED PARTICLES (AP) Electrons Electrons Electrons
E_MAX_AP [keV] 300 400 25×103
BEAM X-Rays X-Rays X-Rays
DOSE RATE [GY s-1] 107 < 10−1 < 1
GY PER PULSE 0.2–1
COST [€] 3×105 <105 106–107
PFMA-3 is able to deliver 1015 electron per shot. The PF phenomena arising in the so called “pinch phase” [28] are in the range of the tens of nanoseconds.
https://doi.org/10.1371/journal.pone.0199312.t002
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Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI)
staining and cell cycle analysis
To determine the extent of apoptosis induction after radiation treatment, flow cytometric anal-
ysis of Annexin V-FITC/PI-stained samples was performed using AnnexinV-FITC Apoptosis
detection kit (eBioscience Dx Diagnostics, Vienna, Austria) as previously reported [33]. Cell
cycle analysis was carried out using a PI/RNaseA staining according to standard procedures.
All the flow cytometric analyses were performed on an FC500 flow cytometer (Beckman,
Miami, FL, USA), with the appropriate software (CXP, Beckman).
Western blot analysis
Western blot analysis were performed as previously detailed [34]. Cells were lysed using the
M-PER Mammalian Protein Extraction Reagent, supplemented with the Protease and Phos-
phatase Inhibitor Cocktail (Thermo Fisher Scientific Inc., Rockford, IL, USA). Equivalent
amounts of protein in each sample (about 40 μg) were separated by gradient gels (4%–20%
acrylamide). Analysis with an antibody to β-actin documented equal protein loading. Antibod-
ies to caspase-9 (#9508, 1:1000, anti–mouse), caspase -8 (#9927, 1:1000, anti–mouse), Bcl-xL
(#2762, 1:1000, anti–rabbit), cyclin B1 (#4138, 1:1000, anti–rabbit), E-Cadherin (#3195,
1:1000, anti–rabbit), Phospho-p53 (Ser15) (#9284, 1:1000, anti–rabbit), β-actin (#8457, 1:1000,
anti–rabbit) were all from Cell Signaling Technology (Danvers, MA, USA).
Clonogenic assay
Control and treated cells were seeded in 6-well plates at 500–5000 cells per well (four replicates
of each sample) with 3 ml complete medium. Cells were incubated to allow colony formation
and medium was changed every three days. After 9 days, cells were washed twice with phos-
phate–buffered saline (PBS), fixed with 10% formaldehyde (Sigma) and stained with 0.01% (w/v)
crystal violet (Sigma-Aldrich, Steinheim, Germany). Air–dried colonies containing more than 50
individual cells were counted under a stereomicroscope (Bausch & Lomb, Rochester, NY, USA).
The Plating Efficiency (PE) was calculated by dividing the number of counted colonies by the
number of seeded cells. The Surviving Fraction (SF) was calculated by normalizing the PE values
of irradiated samples to PE values of corresponding control and a survival curve was generated.
Senescence assay
Ninety-six hrs after irradiation control and treated cells were seeded onto a glass slide. Beta
galactosidase activity at pH 6 was detected using a Senescence Cells Histochemical Staining Kit
(Sigma-Aldrich, St. Louis, MO). The assay was performed according to the manufacturers´
instructions. Senescent cells were detected by formation of local blue precipitate upon enzy-
matic cleavage under a Leitz Orthoplan light microscope (LM, Leica Microsystem Inc., Ban-
nockburn, Ill, USA) [35].
DNA double-strand breaks assay
Three, 24 and 48 hrs after irradiation control and treated cells were seeded on glass slides. Cells
were fixed with 4% formaldehyde for 10 min at room temperature and washed three times with
PBS. To permeabilize the cells, the slides were submersed in a glass jar over a 10-min period
with 0.2% Triton X100 in PBS. The slides were washed three times in PBS. Then, the slides were
incubated in blocking solution (5% bovine serum albumin in PBS) for 1 hour at room tempera-
ture. Primary anti-pospho-Histone-H2A.X (Ser139) (Merck Millipore KGaA, Darmstadt, Ger-
mania) incubation was carried out in 1% bovine serum albumin PBS solution overnight at 4 ˚C
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(1:1000). After three washing steps, cells were then incubated in the secondary antibody FITC-
conjugated (DAKO Denmark A/S Glostrup, Denmark) for 1 hour at room temperature (dilu-
tion 1/30). The slides were washed three times and the nuclei were counterstained with DAPI
(final working concentration of 1 μg/ml in Vectashield). The slides were covered with coverslips
and stored in the dark at– 20˚C. Images were taken under a Zeiss Axio Imager.Z1 microscope
(Zeiss, Jena, Germany), with 40x/NA 0.75 optics, coupled to a computer-driven Zeiss Axio-
CAM digital camera (MRm), using the Zeiss AxioVision (version 4.5) software.
Wound healing assay
The in vitro scratch wound experiments were performed according to previous studies [36].
Briefly, control and treated cells were seeded in 6-well plates (four replicates of each sample)
with 3 ml complete medium and allow reaching confluence. A reproducible longitudinal
scratch in the monolayer was made the following day using sterile micropipette tips. The pro-
cess of wound closure was monitored at different time points (0, 6, 21, 30, 45 hrs) by photo-
graphing the central field of the scratches under an inverted light microscopy (Olympus
CKX41, Olympus Corp, Tokyo, Japan) mounted with a digital camera (C-7070 Wide Zoom,
Olympus) at 10 × magnification. The pictured field was standardized each time against a hori-
zontal line drawn on the base of the plate passing through the center of each well. Morphomet-
ric analysis of cell migration was performed by one experienced investigator blinded to the
specific experimental conditions using a computerized image analysis system (Qwin, Leica
Microsystem Imaging Solution, Ltd). A region of 2.58 x 106μm2 that included the artificial
scratch and the adjacent cell monolayer was selected as the standard region of interest. The
wound healing effect was calculated as (1-Ax/A0) %, where A0 and Ax represented the empty
scratch area at 0 and x hours, respectively.
Glutathione and lipid peroxidation analyses
For detection of intracellular glutathione, SK-Mel28 were incubated (30 min, 37˚ C) with 60 μM
monochlorobimane (mBCl). This non-enzymatic fluorescent reagent when bound to reduced
(GSH) or oxidized (GSSG) glutathione, formed the adduct bimane–glutathione (B-SG), that
emitted a fluorescent blue light (Ex/Em = 380nm/461nm), whereas mBCl unbound was almost
non-fluorescent. For the detection of lipid peroxidation on cells membrane, SK-Mel28 were
incubated (30 min, 37˚ C) with 1 mM boron-dipyrromethene (BODIPY). Oxidation of the poly-
unsaturated butadienyl portion of the dye resulted in a shift of the fluorescence emission peak
from ~590 nm to ~510 nm. Fluorescence images of 100 × magnification were acquired under
the epifluorescence microscope Nikon Eclipse Ti-E (Nikon Instruments Europe B.V., Bologna,
Italy). Scanning electrochemical microscopy (SECM) measurements were performed using an
experimental setup coupling a 910B SECM (CHI Instruments, USA) with a Nikon Ti optical
microscope (Nikon Instruments Europe B.V., Bologna, Italy). All electrochemical measure-
ments were carried out in a 35 mm Petri dish located on the plate holder of the inverted micro-
scope and used to allocate the Mylar1. The SECM probes were 10 μm diameter platinum ultra-
microelectrodes (UMEs). The RG value of all the Pt UMEs used in the present work was 10. An
Ag/AgCl/3 M KCl electrode was used as a reference electrode and a platinum wire as the counter
electrode. The translational rate of the UME for the SECM images was 25 μm/s.
Statistical analysis
The data were presented as the mean values from at least three separate experiments ± SD or
SEM. Statistical analyses were performed using Student’s t test at a significance level of P
<0.05 (GraphPad Prism Software).
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Results
1) PFMA-3 very high dose rate caused radiation-induced clonogenic cell
death greater than XRT
SK-Mel28 and A375 cells were irradiated at a high DR (pulses of 0.2 Gy in 20 to 50 ×10−9 sec)
by PFMA-3 and, in the same experimental conditions, by the XRT device calibrated to mimic
PFMA-3 energy spectrum. Cells were seeded 20 hrs before irradiation and treated at 2, 4 and 8
Gy. We examined the anti-proliferative effect of the two X-ray sources through clonogenic
assay, the “gold standard” for radiation effect studies. Fig 1a showed the dose-response curves
for cell killing induction. In response to PFMA-3 irradiation, the survival fractions at 2 Gy
(SF2) were 0.19 for SK-Mel28 and 0.40 for A375; in contrast XRT SF2 were nearly 1 for
SK-Mel28 and 0.66 for A375. PFMA-3 SF4 and SF8 decreased to 0.04 and 0.02 for SK-Mel28
and to 0.07 and 0.06 for A375 respectively.
Instead, for the XRT device the SF4 and SF8 were 0.53 and 0.12 for the SK-Mel28 and 0.28
and 0.22 for the A375. The survival curves for SK-Mel28 were fitted using a modified standard
linear quadratic model [20] to evaluate 50% survival dose(D50). D50 values for SK-Mel28
were 1.25 Gy for PFMA-3 and 4.3 Gy for XRT, confirming that PFMA-3 treatments were
more effective than XRT ones to decrease ability of SK-Mel28 to form a clone (Fig 1b). D50
values for A375 were 1.6 Gy for PFMA-3 and 2.7 Gy for XRT. In Fig 1b we also reported the
relative biological effect, RBE, evaluated relative to 50% survival using, as standard reference,
the XRT radiation.
2) PFMA-3 very high dose rate induced a more severe DNA damage with
respect to XRT
Induction of DNA double-strand breaks (DNA-DSB) is one of the key mechanisms underly-
ing IR antiproliferative effect. A very early step in the cellular response to DSB is the phos-
phorylation at serine 139 of a histone H2A variant, H2A.X, at the sites of DNA damage
[4]. Pospho-H2A.X at Ser139 was detected by immunofluorescence and analyzed under
microscope. SK-Mel28 samples treated with 2 Gy PFMA-3 showed a great pospho-H2A.X
fluorescence after 3 hrs. This DNA damage tended to disappear at 24 and 48 hrs. Interest-
ingly, 2 Gy XRT treatment induced a lower damage at 3 hrs (Fig 2a). Also in A375 samples
2Gy PFMA-3 irradiation caused a higher H2A.X phosphorylation in comparison to XRT
(Fig 3a).
Four and 8 Gy PFMA-3 caused a similar damage with respect to 2 Gy treatment at 3 hrs in
SK-Mel28 cells but the effect lasted longer, until 24 and 48 hrs. In 4 and 8 Gy XRT samples we
observed a significantly less pronounced increase of phospho-Ser139 H2A.X at all time points
(Fig 2b and 2c). At 4 and 8 Gy also A375 trend was similar to SK-Mel28 (Fig 3b and 3c). It is
well known that tumor suppressor protein p53 is a central stress protein in DNA damage
response [38]. We studied the effects of PFMA-3 and XRT irradiation on the phosphorylation
status of p53 at Ser15 in our cell models. In SK-Mel28 western blot analysis documented that
PFMA-3 was able to enhance Ser15 p-p53 at all doses. On the contrary, XRT did not induce a
p-p53 increase but rather a little inhibition respect to control (Fig 2d). Also for A375 cells it
was evident that PFMA-3 enhanced Ser15 p-p53 levels, mostly at 8 Gy. XRT treatment con-
firmed its weak effect (Fig 3d). Taken together these results clearly showed that PFMA-3
induced a greater, less easy-to-repair DNA-DSB and a consequent more important p53 activa-
tion in comparison to XRT in both cell lines.
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3) PFMA-3 and XRT treatments did not induce significant apoptotic events
until 96 hours
IR therapy, like other types of anticancer treatments, may induce multiple forms of cell death.
Apoptosis is the major modality observed in response to irradiation. It is mostly induced in
hematopoietic cells or in p53 wildtype tumor cells, but it is well known that final cell death
Fig 1. PFMA-3 causes radiation-induced clonogenic cell death greater than XRT. (a) Colony forming unit assay on SK-Mel28 and A375 cells
irradiated with PFMA-3 and XRT at 2, 4 and 8 Gy. Data are representative of three independent experiments performed in triplicate and SD is not
shown being less than 10%. Black (SK-Mel28) and red (A375) asterisks indicate statistically significant differences (P<0.05, P<0.005). (b)
Radiobiological parameters of SK-Mel28 and A375 cell lines for PFMA-3 and XRT 2, 4, 8 Gy irradiation. SF2, SF4 and SF8 survival fraction at 2, 4 and 8
Gy respectively. D50, 50% survival dose. The D50 values for XRT device were used as standard reference for the RBE evaluations. The MLQ curve has
been built from parameters suggested for SK-Mel28 and for low energy X-ray sources with a correction for the exposure time [37].
https://doi.org/10.1371/journal.pone.0199312.g001
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mode is determined by the type of radiation, the dose of radiation and the molecular profile of
the cells [39, 40]. Through flow cytometry analysis we evaluated whether the antiproliferative
effects observed could be related to apoptosis. Fig 4a showed analysis of Annexin V-FITC/PI-
stained SK-Mel28 irradiated with 2 Gy PFMA-3 and XRT.
Fig 2. PFMA-3 causes a DNA-DSB more severe with respect to XRT in SK-Mel28. Induction of DSB was assessed
through detection of phosphorylation of H2A.X at Ser139 (green) by immunofluorescence and microscopy analysis. a)
DSB after 2 Gy treatment. b) DSB after 4 Gy treatment. c) DSB after 8 Gy treatment. ctrl, control cells. d) Western blot
analysis documenting phospho-p53 (Ser51) levels modulation in PFMA-3 and XRT irradiated samples. Antibody to b-
actin served as a loading control. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g002
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Cells were followed for 96 hrs from irradiation and no significant enhancement in the
percentage of early apoptotic (single positive for Annexin V) and/or late apoptotic (double
positive for Annexin V and PI) cells was detected, neither with PFMA-3, nor with XRT. In
addition, 4 Gy irradiation did not induce important increase of Annexin V positive cells
Fig 3. PFMA-3 causes a DNA-DSB more severe with respect to XRT in A375. Induction of DSB was assessed through
detection of phosphorylation of H2A.X at Ser139 (green) by immunofluorescence and microscopy analysis. a) DSB after 2
Gy treatment. b) DSB after 4 Gy treatment. c) DSB after 8 Gy treatment. ctrl, control cells. d) Western blot analysis
documenting phospho-p53 (Ser51) levels modulation in PFMA-3 and XRT irradiated samples. Antibody to b-actin served as
a loading control. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g003
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(Fig 4b). Analysis of 8 Gy treated samples showed a higher percentage of necrotic cells (PI pos-
itive), both in PFMA-3 and XRT but only at 96 hrs the difference was statistically significant
(Fig 4c). Western blot analysis of some apoptotic markers, caspase-9, -8 and Bcl-XL in PFMA-
3 and XRT 2, 4 and 8 Gy treated cells correlated with flow cytometric studies. These data
Fig 4. PFMA-3 and XRT treatments did not induce significant apoptotic events until 96 hours. Flow cytometric
analysis of Annexin V-FITC/PI-stained SK-Mel28 cells treated with a) 2 Gy b) 4 Gy c) 8 Gy PFMA-3 and XRT at
different time points. The percentages of early apoptotic cells (Annexin V FITC+/PI-), late apoptotic/necrotic cells
(Annexin V FITC+/PI+) and necrotic cells (Annexin V FITC-/PI+) were plotted. The histograms were representative
of three separate experiments. Asterisks indicated statistically significant differences (P<0.005). ctrl, control cells. d)
Western blot analysis documenting some apoptotic marker levels modulation in PFMA-3 and XRT irradiated samples.
Antibody to b-actin served as a loading control. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g004
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suggested that up to96 hrs of treatment apoptosis was not the SK-Mel28 primary process of
death after irradiation (Fig 4d).
4) PFMA-3 very high dose rate altered SK-Mel28 cell cycle distribution
more severely than XRT and finally induced the appearance of a sub-G1
peak
To better characterize biological effects of the very high DR delivered on cancer cells survival,
we proceeded to consider irradiation cytostatic effects through cell cycle distribution analysis.
In 2 Gy PFMA-3 treated cells cytostatic effects were weak, because a moderate accumulation
in the G2/M phase (about 24%) was visible only after 96 hrs. Two Gy XRT cells did not show
any significant effect in cell cycle distribution (Fig 5a).
Conversely, in 4 Gy PFMA-3 samples a real cell cycle arrest in the G2/M phase (about 50%)
occurred already after 24 hrs and lasted until 120 hrs. Very interestingly, the 4 Gy XRT treat-
ment was not able to produce this effect (Fig 5b). Eight Gy treated sample analysis showed a
greater G2/M arrest, about 60% after 24 hrs and, at 120 hrs, sub-G1 peak (apoptotic cells)
reached about 24% (Fig 5c). Even at this high dose, XRT cytostatic effect was weak and much
lower in comparison with PFMA-3. Therefore, at early times and up to 96 hrs, in SK-Mel28
the prevailing PFMA-3 effect consisted in cellular cell cycle shift to G2/M phase, preceding by
a few hours the display of the peculiar endonucleases-induced DNA cuts, liable for the appear-
ance of sub-G1 peak. These results have been molecularly strengthened through western blot
analysis of the levels of cyclin B1 that, together with cdc2, forms the mitosis-promoting factor
(MPF). Fig 5d showed that PFMA-3 irradiation induced a cyclin B1 decrease at all doses and
mostly at 24 hrs after treatment. It was well known that cyclin B1 reduction correlates with
G2/M arrest [40]. In contrast, after XRT treatment (at all doses) cyclin B1 levels remained con-
stant. These results elucidated that PFMA-3 antiproliferative prevalence was due to cytostatic
instead of cytotoxic effects.
5) PFMA-3 very high dose rate caused higher levels of stress-induced
premature senescence with respect to XRT
Having noted the consistent G2/M arrest concurrently with the absence of evident apoptotic
effects, we hypothesized that a stress-induced premature senescence (SIPS) might account for
the greater effect of PFMA-3. In fact, it has been demonstrated that as well as an irreversible
arrest in the G1 phase of the cell cycle [41, 42], senescence could also be induced during a pro-
longed G2 arrest [43–45]. Therefore, senescence activated β-gal (SA- β-gal) activity was mea-
sured (at 96 hrs) through a histochemical staining kit, X-gal based. Two, 4 and 8 Gy PFMA-3
samples expressed a number of β-gal positive cells significantly higher than control cells and
respect to XRT samples (Fig 6).
6) PFMA-3 very high dose rate affected cell migration properties more than
XRT
We performed scratch wound-healing assay to evaluate very high DR effects also on SK-Mel28
and A375 migration ability. This assay is a commonly accepted and well-developed method to
measure cell migration in vitro [46, 47]. After irradiation cells were seeded and, once the
proper confluence reached, they were scratched. The process of wound closure, driven by the
migration of cells into the wounded area, was monitored under stereomicroscope at different
time points until 45 hrs after scratching. Figs 7a and 8 showed that repair in XRT samples was
always greater than in PFMA-3 at all doses and all time points for both cell lines.
Radiosensitivity and very high dose rate pulses
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In particular, for SK-Mel28 XRT maximum repair (60%) was obtained at 2 Gy after 45 hrs
(at the same time control sample repair was 73%), whereas PFMA-3 maximum repair was
about 40%. A375 trend was very similar. We completed this analysis with an expression study
of E-cadherin protein levels after irradiation in SK-Mel28 samples. Epithelial cadherin (E-cad-
herin) is a major cell-cell adhesion molecule that interconnects epithelial cells [48–50]. In can-
cer cells, the loss or decrease in E-cadherin expression and/or function typically correlates
Fig 5. PFMA-3 very high dose rate altered SK-Mel28 cell cycle distribution more severely than XRT and finally
induced the appearance of sub-G1 peak. Flow cytometric analysis of cell cycle distribution in SK-Mel28 cell line
treated with a) 2 Gy b) 4 Gy c) 8 Gy PFMA-3 and XRT for different times. The histograms were representative of three
separate experiments. ctrl, control cells. d) Western blot analysis documenting cyclin-B1 levels modulation in PFMA-3
and XRT irradiated cells. Antibody to b-actin served as a loading control. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g005
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with high invasiveness and metastasis [49, 50]. After 2 Gy PFMA-3 treatment, E-cadherin
levels increased (at 24 hrs). This enhancement was more evident in 4 Gy PFMA-3 samples
(24 hrs) and raised again in 8 Gy PFMA-3 ones. On the contrary, levels of E-cadherin were
reduced with respect to control, after all doses XRT irradiation (Fig 7b). Taken together these
data suggested that very high DR played a role also in SK-Mel28 and A375 migration/invasive-
ness mechanisms.
7) PFMA-3 very high dose rate increased glutathione and lipid
peroxidation more than XRT
It is well known that IR can directly interact with target macromolecules or indirectly with
water, leading to a radiolysis process and to the generation of reactive oxygen and nitrogen
species (ROS/RNS) that can affect several cellular functions, such as the mitochondrial metab-
olism [51]. The transient cellular response to the induced oxidative stress (protective mecha-
nism) is strongly correlated to the radiation dose and quality [51]. The reducing agent
glutathione (GSH) is considered a free radical scavenger while it is converted into its oxidized
form glutathione disulfide (GSSG) [52]. The synthesis and metabolism of GSH are well bal-
anced within the cell and their alteration can compromise the defense against ROS [53]. In
order to evaluate how the DR of the impacting radiation is critical in determining an effect on
the oxidative and metabolic balance we investigated the variation of glutathione levels and the
lipid peroxidation in irradiated cells compared to control. Fig 9a showed that the fluorescence
of the adduct bimane–glutathione (B-SG) induced in SK-Mel28 after PFMA-3 irradiation was
higher, in a dose dependent manner, than after XRT treatment.
Since monochlorobimane (mBCl) only qualitatively indicates the glutathione levels
between compared samples, we also performed scanning electrochemical microscopy (SECM)
experiments capable to specifically quantify the GSH levels of each sample. In Fig 9b and 9c
the images and the graphs of regeneration currents at SECM ultramicroelectrode measured
employing ferrocene-methanol (FcMeOH) redox mediator for control (ctrl), PFMA-3 and
Fig 6. PFMA-3 caused higher levels of SIPS respect to XRT. Representative images of staining for senescence-associated β-galactosidase 96 hrs
following irradiation with 2, 4 and 8 Gy PFMA-3 and XRT. Data were representative of three independent experiments. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g006
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XRT irradiated cells were reported. The regeneration currents are strictly correlated to GSH/
GSSG levels. In particular, increase of the regeneration current is associated to increased levels
of GSH/GSSG ratio and coupled with the capacity of specific enzymes (glutathione dehydroge-
nase and glutathione reductase) to regenerate the redox mediator GSH. The higher positivity
of the mBCl test and the larger regeneration currents found 3 hrs after PFMA-3 irradiation
suggested a radiation-induced increment of the GSH levels. We also detected by the boron-
dipyrromethene (BODIPY) fluorescent adduct (Fig 9a) a raise of the lipid peroxidation. The
GSH/GSSG ratio and the lipid peroxidation of the XRT irradiated cells did not appear to differ
significantly from that of the control cells indicating that the radiation effect is DR dependent.
Discussion
Improvements in RT over the last decade are linked to the emergence of intensity-modulated
techniques (IMRT) that modify DR treatment delivery and to the use of proton or heavy ions
species [54]. Hadrontherapy and proton radiotherapy have recently attracted growing interest.
Fig 7. PFMA-3 affected SK-Mel28 migration abilities more than XRT. a) Cell migration behaviour was evaluated during
performance of a wound-healing assay after treatment with 2 Gy, 4 Gy and 8 Gy PFMA-3 and XRT. Data were representative of
three independent experiments performed in quadruplicate. ctrl, control cells. Asterisks indicated statistically significant
differences (P<0.05, P<0.005, P<0.0005). b) Western blot analysis documenting E-cadherin levels modulation in
PFMA-3 and XRT irradiated samples. b-actin loading control was not shown. ctrl, control cells.
https://doi.org/10.1371/journal.pone.0199312.g007
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In fact, superior ballistic properties of charged particles with respect to photons can be trans-
lated in higher dose conformity and less involvement of healthy tissue. However, the need
for cost reduction is driving the development of new, more compact and economic technolo-
gies. The PFMA-3 device was designed to produce a thin plasma leaf through the fast and syn-
chronized discharge of the capacitor bank. When the plasma leaf collapses in the so-called
“pinch”, the plasma reaches thermonuclear conditions of pressure and energy density for a few
tenths of nanoseconds (Table 1). Depending on the chamber filling gas, nitrogen in our experi-
ments, several kinds of radiation fields are produced. Among those, a naturally collimated elec-
tron beam is driven to collide with a target to produce X-Rays. This electron bunch is very
intense (0.1 mC) with 1015 electrons produced [13]. It is this fast and impressive production
that makes the difference, in terms of DR, with other technologies. Moreover, PFMA-3
manufacturing, utilization and radiation protection arrangements require quite low costs in
contrast to the high application flexibility (Table 2). Preliminary data about antitumor efficacy
of PFMA-3 have been obtained in glioblastoma (T98G cell line) [12] and breast cancer preclin-
ical models (MCF-7 cell line) [13]. Although the effects of an important DR variation after
low-LET radiation has been reported for several years [55], up to now limited recent biological
data have been published on very high DR effect in tumor. The present work hypothesized
that the very high DR delivered by PFMA-3 significantly impaired radioresistant melanoma
survival in comparison with a conventional XRT. As indicated by CFU assay, PFMA-3 treat-
ment had a higher antiproliferative power with respect to XRT. In particular, the D50 (50%
survival dose) was 3.4 fold and 1.7 fold lower than the XRT D50 for SK-Mel28 and A375
respectively. These values are very interesting and it would be worthwhile to deeply investigate
them in comparison with the heavier charged particles. This could have important therapeutic
implications because tumor could be treated with lower total doses, hence with likely lower
Fig 8. PFMA-3 affected A375 migration abilities more than XRT. Cell migration behaviour was evaluated during
performance of a wound-healing assay after treatment with 2 Gy, 4 Gy and 8 Gy PFMA-3 and XRT. Data were
representative of three independent experiments performed in quadruplicate. ctrl, control cells. Asterisks indicated
statistically significant differences (P<0.05, P<0.005, P<0.0005).
https://doi.org/10.1371/journal.pone.0199312.g008
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Fig 9. PFMA-3 induced glutathione and lipid peroxidation production greater than XRT. a) Visualization of the
SK-Mel28 living cells 3 hrs after irradiation with PFMA-3 or XRT (at 2 and 4 Gy) and of those non irradiated (ctrl)
loaded by the fluorescent dyes monochloromobimane (mBCl) and boron-dipyrromethene (BODIPY) for a qualitative
GSH and lipid peroxidation detection, respectively. Epifluorescence images at 100 × of magnification. b)
Representative FcMeOH/SECM images in constant height mode of non irradiated (ctrl) and irradiated SK-Mel28 cells
Radiosensitivity and very high dose rate pulses
PLOS ONE | https://doi.org/10.1371/journal.pone.0199312 June 29, 2018 16 / 21
incidence of radiation-induced damage to healthy tissues. We described how PFMA-3 antipro-
liferative effect resulted by a greater and less easy-to-repair DNA-DSB and a consequent higher
p53 activation in both cell lines. As showed by Annexin V flow cytometric analysis and by cas-
pases and Bcl-XL western blot assessment, apoptotic cell death was not the principal inhibitory
effect exerted by both sources on SK-Mel28 line, at least until 96 hrs. The preferential response
to IR seemed to be the cell cycle arrest and the premature senescence induction [56–58], Cell
cycle distribution and SA- β-gal activity studies elucidated that, in SK-Mel28, PFMA-3 preva-
lence emerged in connection with cytostatic rather than cytotoxic effects. The immunofluores-
cence and electrochemical analyses revealed that higher levels of GSH and a greater lipid
peroxidation were induced by the PFMA-3 source, corroborating the view that SIPS is aneffect
of the oxidative stress and that cellular senescence is a mechanism of radiosensitization likely
induced by a ROS-mediated DNA damage [59] DR dependent. Finally, our characterization
showed that PFMA-3 impaired both cell lines migration properties more than XRT and this
was confirmed by the parallel increase of E-cadherin levels (in SK-Mel28). Since it is well
known that the adhesion of cells to extracellular matrix (ECM) as well as to other cells can pos-
itively modulate the resistance to RT [60, 61] our results implicated that a lower migration
capability could also express a lower radioresistance. The present study confirmed the innova-
tive features of DR and therefore of the radiation source for the optimization of radiotherapy
application. However further experiments and a more specific approach are required to estab-
lish mechanistic molecular basis of the observed PFMA-3 superior biological effects.
Conclusions
With this in vitro characterization, we provided a contribution to understanding the greater
effectiveness of ultra-high dose rate energy delivery in impairing proliferation of melanoma
cell lines SK-Mel28 and A375, known to be resistant to radiation damage. These preliminary
results represent an encouraging first step for future preclinical characterizations. This work
could also have important future perspectives for the development of a novel class of Plasma
Focus technology-based devices, therapeutically performing, with low costs and established
technologies.
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